Corrections to Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial, [Lancet Respir Med, (2015)] DOI: 10.1016/S2213-2600(15)00245-3;Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: A randomised, double-blind, placebo-controlled, phase 2b trial

The Lancet Respiratory Medicine

Volumn 3, Issue 9, 2015, Pages 684-691

  Alton, Eric W F W ^b   Armstrong, David K ^g   Ashby, Deborah ^b   Bayfield, Katie J ^b   Bilton, Diana ^a   Bloomfield, Emily V ^b   Boyd, A Christopher ^f   Brand, June ^f   Buchan, Ruaridh ^c   Calcedo, Roberto ⁱ   Carvelli, Paula ^b   Chan, Mario ^b   Cheng, Seng H ^j   Collie, D David S ^e   Cunningham, Steve ^g   Davidson, Heather E ^f   Davies, Gwyneth ^b   Davies, Jane C ^b   Davies, Lee A ^h   Dewar, Maria H ^c   Doherty, Ann ^f   Donovan, Jackie ^a   Dwyer, Natalie S ^b   Elgmati, Hala I ^c   Featherstone, Rosanna F ^b   Gavino, Jemyr ^b   Gea Sorli, Sabrina ^b   Geddes, Duncan M ^a   Gibson, James S R ^f   Gill, Deborah R ^h   Greening, Andrew P ^c   Griesenbach, Uta ^b   Hansell, David M ^a   Harman, Katharine ^b   Higgins, Tracy E ^b   Hodges, Samantha L ^b   Hyde, Stephen C ^h   Hyndman, Laura ^f   Innes, J Alastair ^c   Jacob, Joseph ^a   Jones, Nancy ^a   Keogh, Brian F ^a   Limberis, Maria P ⁱ   Lloyd Evans, Paul ^k   Maclean, Alan W ^f   Manvell, Michelle C ^b   McCormick, Dominique ^h   McGovern, Michael ^c   McLachlan, Gerry ^e   Meng, Cuixiang ^b   Montero, M Angeles ^a   Milligan, Hazel ^c   Moyce, Laura J ^h   Murray, Gordon D ^d   Nicholson, Andrew G ^a   Osadolor, Tina ^a   Parra Leiton, Javier ^f   Porteous, David J ^f   Pringle, Ian A ^h   Punch, Emma K ^b   Pytel, Kamila M ^b   Quittner, Alexandra L ^l   Rivellini, Gina ^b   Saunders, Clare J ^b   Scheule, Ronald K ^j   Sheard, Sarah ^a   Simmonds, Nicholas J ^a   Smith, Keith ^k   Smith, Stephen N ^b   Soussi, Najwa ^b   Soussi, Samia ^b   Spearing, Emma J ^b   Stevenson, Barbara J ^f   Sumner Jones, Stephanie G ^h   Turkkila, Minna ^b   Ureta, Rosa P ^b   Waller, Michael D ^b   Wasowicz, Marguerite Y ^b   Wilson, James M ⁱ   Wolstenholme Hogg, Paul ^j   more..

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e UNIVERSITY OF EDINBURGH   (United Kingdom)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

^g ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j SANOFI   (France)

^k NHS BLOOD AND TRANSPLANT   (United Kingdom)

^l UNIVERSITY OF MIAMI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; LIPOSOME; PLACEBO; PLASMID VECTOR; CFTR PROTEIN, HUMAN;

ADULT; ARTICLE; CFTR GENE; CONTROLLED STUDY; CYSTIC FIBROSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FLU LIKE SYNDROME; FORCED EXPIRATORY VOLUME; GENE; GENE MUTATION; GENE TRANSFER; HUMAN; LIPOSOMAL DELIVERY; MAJOR CLINICAL STUDY; MALE; NEBULIZATION; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; ADMINISTRATION AND DOSAGE; ADOLESCENT; CHILD; CLINICAL TRIAL; DRUG EFFECTS; GENE THERAPY; GENETICS; INHALATIONAL DRUG ADMINISTRATION; MULTICENTER STUDY; MUTATION; NEBULIZER; PATHOPHYSIOLOGY; PLASMID; PROCEDURES; UNITED KINGDOM; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GENETIC THERAPY; HUMANS; LIPOSOMES; MALE; MUTATION; NEBULIZERS AND VAPORIZERS; PLASMIDS; UNITED KINGDOM; YOUNG ADULT;

EID: 84941179388     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(15)00314-8     Document Type: Erratum

References (25)

1. Griesenbach U, Alton EW Moving forward: cystic fibrosis gene therapy. Hum Mol Genet 2013, 22:R52-R58.
2. UK Cystic Fibrosis Registry annual data report 2013 Cystic Fibrosis Trust, (accessed April 26, 2015). http://www.cysticfibrosis.org.uk/media/598466/annual-data-report-2013-jul14.pdf.
3. Gill DR, Hyde SC Delivery of genes into the CF airway. Thorax 2014, 69:962-964.
4. Davies LA, Nunez-Alonso GA, McLachlan G, Hyde SC, Gill DR Aerosol delivery of DNA/liposomes to the lung for cystic fibrosis gene therapy. Hum Gene Ther Clin Dev 2014, 25:97-107.
5. McLachlan G, Davidson H, Holder E, et al. Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung. Gene Ther 2011, 18:996-1005.
6. Alton EW, Baker A, Baker E, et al. The safety profile of a cationic lipid-mediated cystic fibrosis gene transfer agent following repeated monthly aerosol administration to sheep. Biomaterials 2013, 34:10267-10277.
7. Alton EW, Boyd AC, Cheng SH, et al. Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung. Gene Ther 2014, 21:89-95.
8. Hyde SC, Pringle IA, Abdullah S, et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008, 26:549-551.
9. Quittner AL, Sawicki GS, McMullen A, et al. Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national sample. Qual Life Res 2012, 21:1267-1278.
10. Kerem E, Konstan MW, De Boeck K, et al. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014, 2:539-547.
11. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999, 340:23-30.
12. Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003, 290:1749-1756.
13. Boyle MP, Bell SC, Konstan MW, et al. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med 2014, 2:527-538.
14. Leigh MW, Kylander JE, Yankaskas JR, Boucher RC Cell proliferation in bronchial epithelium and submucosal glands of cystic fibrosis patients. Am J Respir Cell Mol Biol 1995, 12:605-612.
15. Chadwick SL, Kingston HD, Stern M, et al. Safety of a single aerosol administration of escalating doses of the cationic lipid GL-67/DOPE/DMPE-PEG5000 formulation to the lungs of normal volunteers. Gene Ther 1997, 4:937-942.
16. Alton EW, Stern M, Farley R, et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999, 353:947-954.
17. Gill DR, Southern KW, Mofford KA, et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997, 4:199-209.
18. Zabner J, Cheng SH, Meeker D, et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997, 100:1529-1537.
19. Bazzani RP, Cai Y, Hebel HL, Hyde SC, Gill DR The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung. Biomaterials 2011, 32:9854-9865.
20. Hyde SC, Southern KW, Gileadi U, et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000, 7:1156-1165.
21. Rose AC, Goddard CA, Colledge WH, Cheng SH, Gill DR, Hyde SC Optimisation of real-time quantitative RT-PCR for the evaluation of non-viral mediated gene transfer to the airways. Gene Ther 2002, 9:1312-1320.
22. Konstan MW, Davis PB, Wagener JS, et al. Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution. Hum Gene Ther 2004, 15:1255-1269.
23. Jones AP, Wallis C Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010, 3. CD001127.
24. Wilms EB, Touw DJ, Heijerman HG, van der Ent CK Azithromycin maintenance therapy in patients with cystic fibrosis: a dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatr Pulmonol 2012, 47:658-665.
25. Report of the workshop on endpoints for cystic fibrosis clinical trials European Medicines Agency, (accessed April 26, 2015). https://www.ecfs.eu/files/webfm/webfiles/File/documents/EMA_Workshop2012.pdf.